?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ?d T cell immunotherapy landscape. In five chapters, field experts discuss the challenges facing ?d T cell oncoimmunotherapy, propose solutions, and map next steps. Particular attention is given to summarizing our understanding of the complex, translationally relevant human ?d T cell biology, the evidence basis for designing ?d T cell combination trials and data-driven perspectives on what is known—and what isn’t—about ?d T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering. A chapter is dedicated to the systematic review of all ?d T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of ?d T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering. ?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ?dT cell immunotherapy, which is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Insert - p. iii 7. Aims and scope of series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. iii 8. About the series editor - p. iii 9. Volume editor biography - p. xi 10. Preface - p. xiii 11. Contributors - p. xv 12. Chapter 1. Exploiting fundamental γδ T cell immunobiology in cancer immunotherapy - p. 1 13. Chapter 2. Examining γδ T cell receptor (γδ-TCR) structure and signaling in the context of cellular immunotherapy design - p. 35 14. Chapter 3. γδ T cell immunotherapy: Requirement for combinations? - p. 61 15. Chapter 4. Appraising γδ T cell exhaustion and differentiation in the context of synthetic engineering for cancer immunotherapy - p. 77 16. Chapter 5. γδ T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials - p. 114 17. Chapter 6. Allograft persistence: The next frontier for allogeneic γδ T cell therapy - p. 155 18. Index - p. 185
?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ?d T cell immunotherapy landscape. In five chapters, field experts discuss the challenges facing ?d T cell oncoimmunotherapy, propose solutions, and map next steps. Particular attention is given to summarizing our understanding of the complex, translationally relevant human ?d T cell biology, the evidence basis for designing ?d T cell combination trials and data-driven perspectives on what is known—and what isn’t—about ?d T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering. A chapter is dedicated to the systematic review of all ?d T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of ?d T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering. ?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ?dT cell immunotherapy, which is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Insert - p. iii 7. Aims and scope of series “Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy” - p. iii 8. About the series editor - p. iii 9. Volume editor biography - p. xi 10. Preface - p. xiii 11. Contributors - p. xv 12. Chapter 1. Exploiting fundamental γδ T cell immunobiology in cancer immunotherapy - p. 1 13. Chapter 2. Examining γδ T cell receptor (γδ-TCR) structure and signaling in the context of cellular immunotherapy design - p. 35 14. Chapter 3. γδ T cell immunotherapy: Requirement for combinations? - p. 61 15. Chapter 4. Appraising γδ T cell exhaustion and differentiation in the context of synthetic engineering for cancer immunotherapy - p. 77 16. Chapter 5. γδ T cells for cancer immunotherapy: A 2024 comprehensive systematic review of clinical trials - p. 114 17. Chapter 6. Allograft persistence: The next frontier for allogeneic γδ T cell therapy - p. 155 18. Index - p. 185
